JSKN016 + furmonertinib

JSKN016 + furmonertinib is an investigational drug combination consisting of JSKN016, a bispecific antibody-drug conjugate (ADC) targeting HER3 and TROP2, and furmonertinib, an oral third-generation small molecule tyrosine kinase inhibitor selective for mutant forms of the epidermal growth factor receptor (EGFR). JSKN016 is designed to induce apoptosis in tumor cells expressing HER3 and/or TROP2 by delivering a cytotoxic topoisomerase I inhibitor payload while also exerting a bystander effect against neighboring antigen-negative cells. Furmonertinib inhibits EGFR tyrosine kinase activity, especially in NSCLC patients with activating EGFR mutations, and demonstrates high activity against both common and uncommon EGFR mutations, as well as improved brain penetration. The combination is being studied for use in advanced or metastatic solid tumors, particularly non-small cell lung cancer (NSCLC).

Other names

JSKN016 + furmonertinib mesilateJSKN016 + alflutinib